New FDA-Cleared Microbroth Dilution Susceptibility Testing Plate Expands Patient Treatment Options for Gram Negative Infections
EAST GRINSTEAD, England, June 29, 2017 /PRNewswire/ -- A new FDA-cleared microbroth dilution plate for antimicrobial susceptibility (AST) of Gram negative organisms is now available in the U.S., including two of the latest novel compounds, ceftolozane/tazobactam and ceftazidime/avibactam. The plate enables microbiology laboratories to measure true minimum inhibitory concentration (MIC) values of 24 antimicrobials, which are critical in reducing antimicrobial resistance, providing greater sensitivity for better resistance tracking. True MIC values are also the best measure of antibacterial effect, which can assist with therapeutic choices and promote overall better patient care.
Part of the Thermo Scientific Sensititre ID/AST System, the new Sensititre Gram Negative GN6F Plate can be read using a range of options, from manual methods to full automation. Recognized for having one of the largest, most up-to-date selections of antimicrobials, the Sensititre System includes a range of standard plates, as well as the ability to create custom plates tailored to a laboratory's formulary, dilution ranges and patient population, eliminating offline tests and reducing costs.
"When pharmaceutical companies introduce new compounds, the need for an AST device becomes critical, as that will enable microbiology labs to utilize the drug to test patient samples, giving clinicians the results they need to begin utilizing the new compound for patient treatment, said Finn Albrechtsen, vice president of R&D and business development, Thermo Fisher Scientific. "Laboratories can count on the Sensititre System for being at the forefront for providing a standard solution that can be implemented quickly."
More information on the Thermo Scientific Sensititre System can be found here, by visiting http://www.thermofisher.com, or by contacting microbiology@thermofisher.com.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of $18 billion and more than 55,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our premier brands - Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services - we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. For more information, please visit www.thermofisher.com.
Contact Information:
Carlene Graham
Phone: 800-871-8909 x3224109
E-mail: carlene.graham@thermofisher.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/new-fda-cleared-microbroth-dilution-susceptibility-testing-plate-expands-patient-treatment-options-for-gram-negative-infections-300481655.html
SOURCE Thermo Fisher Scientific Inc.
